Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has
Ketamine Assisted Psychotherapy (KAP): Demographics, Data, & Outcomes Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine: A Promising Novel Therapy for Anxiety and PTSD Read More »
John H. Krystal, Chadi G. Abdallah, Gerard Sanacora, Dennis S. Charney, Ronald S. Duman Published online: 6 March 2019 | https://doi.org/10.1016/j.neuron.2019.02.005 Abstract Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy
Ketamine: A Paradigm Shift for Depression Research and Treatment Read More »
Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression.
Ketamine for Treatment-Resistant Mood Disorders Read More »
Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus.
Magnesium And Ketamine In The Treatment Of Depression Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Ketamine Therapy helping veterans battle PTSD Read More »
Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge, Bettina B. Hoeppner, Cristina Cusin, Dawn F. Ionescu, Sanjay J. Mathew, Lee C. Chang, Dan V. Iosifescu, James Murrough, Charles Debattista, Alan F. Schatzberg, Madhukar H. Trivedi, Manish K Jha, Gerard Sanacora, Samuel T. Wilkinson, and George I. Papakostas Published 3 October 2018 | doi: 10.1038/s41380-018-0256-5
Dr. Sanjay Gupta shares the story of Alan Ferguson, who is being treated with ketamine, a powerful anesthetic medication used in hospitals, for severe depression.
CNN Report: Ketamine Offers Lifeline for Suicidal Thoughts Read More »
Rick Doblin is the founder and executive director of MAPS, the Multidisciplinary Association for Psychedelic Studies.
How Ketamine Can Cure Depression Read More »
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
From Chaos To Calm: A Life Changed By Ketamine Read More »